Peters Medical Research | High Point, NC

Research site

(Unclaimed)

Location

665 North Main Street, High Point, North Carolina, United States of America

Site insights

Top conditions

Top treatments

Lubiprostone

Diclofenac

Oxycodone

Vibegron

PRC-4016

CIN-102

Naproxen

Vonoprazan

Eluxadoline

Famciclovir

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 61 total trials

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatme...

Active, not recruiting

Acute Migraine

Drug: Placebo

Drug: Elismetrep (K-304) Dose level 3

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (ASTRO)

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting

Colitis, Ulcerative

Drug: Guselkumab Dose 2

Other: Placebo

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopa...

Enrolling

Idiopathic Gastroparesis

Drug: Placebo

Drug: CIN-102 Dose 15mg

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling

Diabetic Gastroparesis

Drug: Placebo

Drug: CIN-102 Dose 15mg or 10mg

Continuation Protocol for Obstructive Sleep Apnea (OSA)

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only

OSA

Drug: Aroxybutynin and Atomoxetine

Study of the Research Medicine CIN-103 in Adults with Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).

The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with...

Enrolling

Irritable Bowel Syndrome with Diarrhea

Drug: CIN-103

Drug: Placebo